Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Famotidine impurity 10 is a known impurity associated with the histamine H2 receptor antagonist famotidine. This compound is utilized primarily in the analysis of drug purity and stability. Its identification is critical in ensuring the quality and safety of pharmaceutical formulations containing famotidine. Researchers may employ this reagent in the assessment of synthesis methods, formulation development, and regulatory compliance. -
Drug Impurity
Mebendazole impurity 6, also known as 5-Benzoyl-2-benzimidazolinone, serves as a drug impurity of Mebendazole. It is utilized in pharmacological studies to ensure the quality and safety of Mebendazole formulations. Understanding this impurity is critical for evaluating the compound's stability and regulatory compliance in drug development. -
Pranoprofen Impurity
2-(5-Oxo-5H-Chromeno[2,3-b]pyridin-7-yl)propanoic acid is a characterized impurity associated with Pranoprofen, a nonsteroidal anti-inflammatory drug. This compound serves as a useful reference standard in analytical chemistry for the assessment of drug purity and stability. Its presence in research can assist in the evaluation of pharmacological profiles and potential safety assessments of pharmaceutical formulations. -
Drug Impurity
Bupropion impurity 3 is a chemical byproduct associated with the synthesis of bupropion. It serves as a crucial reference standard for assessing the purity and quality of bupropion formulations in pharmaceutical research. The compound is essential for analytical studies focusing on the identification and quantification of drug impurities during the development and quality control processes of bupropion. -
Drug Impurity
Cinacalcet impurity 5 is a chemical impurity associated with the drug Cinacalcet, which functions as a calcimimetic agent targeting the calcium-sensing receptor (CaSR). This impurity may serve as a reference standard in quality control and analytical laboratories to ensure the purity of Cinacalcet formulations. Its characterization is crucial for maintaining stringent pharmaceutical standards and for research applications involving drug stability and degradation studies. -
Drug Impurity
Raloxifene impurity 3 is a structural impurity associated with the selective estrogen receptor modulator Raloxifene. It serves as a key reference standard for the assessment of drug purity and formulation quality control in pharmaceutical research. The compound can be utilized in various analytical techniques to ensure compliance with regulatory standards in drug development. -
Drug Impurity
Candesartan impurity 29 is a byproduct associated with the synthesis of Candesartan, an angiotensin II receptor antagonist. This impurity may be utilized in research to assess the purity and stability of Candesartan formulations. Its characterization is essential for quality control and regulatory compliance in pharmaceutical development. -
Drug Impurity
Azilsartan impurity 4 is a chemical impurity associated with the antihypertensive agent Azilsartan. Its characterization is essential for ensuring the quality and safety of drug formulations. This impurity may be used in the development and validation of analytical methods, providing crucial insights into the stability and integrity of Azilsartan compounds in pharmaceutical research. -
Drug Impurity
Clopidogrel impurity 5, also known as Clopidogrel impurity D, is a structural impurity associated with the pharmaceutical compound Clopidogrel. This reagent is critical for studies assessing the purity and quality of Clopidogrel formulations. It is commonly utilized in pharmaceutical research to investigate potential impurities that may influence drug efficacy and safety profiles. -
Drug Impurity
Edoxaban impurity 15 (Edoxaban N-oxide) serves as a drug impurity associated with Edoxaban. This compound is significant for analytical studies concerning drug quality and stability, as well as for assessing the safety and efficacy profiles of Edoxaban formulations. Its characterization is crucial for regulatory compliance in pharmaceutical development and quality control processes. -
Bupivacaine Impurity
1-(2,6-Dimethylphenyl)-6,7-dihydro-1H-azepin-2(5H)-one is identified as an impurity of Bupivacaine, a widely used local anesthetic. This compound may be utilized in quality control and analytical studies to assess the purity of Bupivacaine formulations. Its presence and characterization are essential for ensuring the safety and efficacy of anesthetic preparations in clinical applications. -
Drug Intermediate
4-(1-Piperazinyl)-1H-Indole hydrochloride is a synthetic intermediate primarily utilized in pharmaceutical synthesis. This compound plays a crucial role in the development of various drugs by facilitating the formation of indole-based scaffolds. Its structural attributes support research into bioactive molecules, making it valuable for medicinal chemistry applications. -
Drug Impurity
Trazodone impurity 17 is a specific impurity of the antidepressant Trazodone, primarily associated with the compound's synthesis. It is essential for researchers to evaluate the quality and safety of pharmaceutical formulations, as impurities can influence drug efficacy and safety profiles. This reagent is valuable for analytical studies, quality control, and pharmaceutical development, providing critical insights into the compound's purity and stability. -
Drug Impurity
Moxifloxacin impurity 9 is a drug impurity derived from the antibiotic Moxifloxacin. As an impurity, it is important for quality control and stability testing in pharmaceutical research and development. Its characterization contributes to understanding the synthesis processes and ensuring the safety and efficacy of Moxifloxacin formulations. -
Drug Intermediate Control
Ethyl 2-(3-hydroxyphenyl)-4-methylthiazole-5-carboxylate is a synthetic intermediate that serves as an essential building block in pharmaceutical synthesis. This compound is designed for applications in drug development, facilitating the formation of various active pharmaceutical ingredients. Its versatile structural features make it a valuable reagent in medicinal chemistry and drug formulation processes. -
Drug Impurity
Rivaroxaban impurity 13 is a chemical impurity associated with the anticoagulant Rivaroxaban. It is utilized primarily in analytical chemistry for method development and validation, particularly in the assessment of drug purity and quality control. This impurity is essential for researchers examining the stability and safety profiles of pharmaceutical formulations containing Rivaroxaban. -
Drug Impurity
Pantoprazole impurity 26 is a characterized impurity associated with Pantoprazole, a proton pump inhibitor. Its presence is of considerable importance in the pharmaceutical industry for ensuring drug quality and compliance with regulatory standards. This compound is often utilized in analytical research for stability studies, purity assessments, and formulation development. -
Drug Impurity
Canagliflozin impurity 12 is a chemical impurity associated with the antidiabetic agent Canagliflozin, which primarily targets the sodium-glucose co-transporter 2 (SGLT2). This impurity is relevant for quality control and pharmacological assessments in the development of Canagliflozin and related compounds. Research applications include method validation, stability testing, and assessing the purity of pharmaceutical formulations. -
Drug Impurity
Solifenacin impurity 10 is a drug impurity associated with Solifenacin. This compound is relevant for analytical chemistry and quality control studies in pharmaceutical research. It serves as a reference standard in the identification and quantification of impurities during Solifenacin synthesis, ensuring compliance with regulatory standards in drug development. -
Perphenazine Impurity
4-[3-(10H-Phenothiazin-10-yl)propyl]-1-piperazineethanol is identified as a Perphenazine impurity. It shares structural similarities with Perphenazine, a typical antipsychotic agent, and serves as a valuable reference compound for analytical studies. This impurity can be utilized in research applications focusing on pharmaceutical development, quality control, and stability testing of Perphenazine-containing formulations. -
Drug Intermediate Control
7-Piperazin-1-yl-thieno[2,3-c]pyridine hydrochloride is a synthetic chemical compound that serves as a key intermediate in pharmaceutical synthesis. Its structure and properties make it valuable for the development of various drug candidates. This reagent is commonly utilized in chemical research to explore new therapeutic avenues and enhance the efficacy of drug formulations. -
Lacosamide Impurity
(Rac)-Desmethyl lacosamide is a known impurity of lacosamide and serves as a significant intermediate in the synthesis of this anticonvulsant drug. This compound can be used in chemical research to study the properties and effects of lacosamide and its derivatives. Its characterization is essential for ensuring the purity and efficacy of lacosamide formulations in therapeutic applications. -
Drug Impurity
Clopidogrel impurity 8 is a metabolite impurity associated with the antiplatelet agent Clopidogrel. This compound is significant for quality control and analytical studies in pharmaceutical research, particularly in assessing the purity of Clopidogrel formulations. It serves as a valuable reference standard for the identification and quantification of impurities in drug development and stability testing. -
Drug Impurity
Fusidic acid impurity 1, also known as 16-Epidesacetylfusidic acid, is a chemical impurity associated with fusidic acid. This compound serves as a significant marker in the quality control of fusidic acid production, aiding in the purification and identification of active pharmaceutical ingredients. Research applications include its use in stability studies and the analysis of drug formulation quality in pharmaceutical development. -
Drug Impurity
Betamethasone acetate impurity 1, also known as Betamethasone 11,21-diacetate, is characterized as a drug impurity of Betamethasone acetate. Its presence can impact the efficacy and safety profiles of pharmaceutical formulations. This compound is essential for quality control and analytical research, providing insight into the purity and stability of corticosteroid products. -
Drug Impurity
Tenofovir impurity 1, also known as Tenofovir impurity E, is a significant impurity of the antiretroviral drug Tenofovir. It is essential for quality control and analytical studies during the synthesis of Tenofovir. Researchers can utilize this compound to assess the purity and stability of Tenofovir formulations in pharmaceutical development and regulatory compliance. -
Drug Impurity
Salmeterol impurity 7, also known as Salmeterol impurity H, is a defined impurity of the bronchodilator Salmeterol. This compound is utilized primarily in drug quality control and analytical studies to ensure the purity and efficacy of pharmaceutical formulations. Its presence in Salmeterol formulations may affect therapeutic outcomes, making it essential for rigorous quality assurance processes in pharmaceutical research and development. -
Drug Impurity
Naproxen impurity 6, also known as Naproxen Nitrile impurity, is a chemical impurity associated with the nonsteroidal anti-inflammatory drug (NSAID) Naproxen. This compound is primarily utilized in the analysis of drug formulations and quality control to ensure the purity and safety of pharmaceutical products. Its understanding is crucial for regulatory compliance and for studying the degradation pathways of Naproxen during storage and processing. -
Drug Impurity
Atorvastatin impurity 7 calcium is a known impurity associated with Atorvastatin calcium, a widely used statin for cholesterol management. As a research reagent, it serves as a reference standard in the characterization and analysis of Atorvastatin formulations. Its identification is crucial for ensuring the quality and safety of pharmaceutical products containing Atorvastatin. -
Drug Impurity
Flurbiprofen impurity 2 is a known impurity of the nonsteroidal anti-inflammatory drug (NSAID) Flurbiprofen. This compound is relevant for quality control and regulatory compliance in pharmaceutical development, as it highlights potential variations in drug purity. It can be utilized in research applications focused on the analysis of drug formulations and the assessment of the safety and efficacy profiles of NSAIDs. -
Drug Impurity
Telmisartan impurity 7, also known as Telmisartan bromo ethyl ester, functions primarily as a drug impurity associated with the pharmaceutical compound Telmisartan. This compound is important for quality control and analytical studies, enabling researchers to assess the purity and stability of Telmisartan formulations. Its analysis can aid in ensuring compliance with regulatory standards in drug development and manufacturing processes. -
Drug Intermediate
Nordiazepam uncyclized intermediate hydrochloride is a prodrug intermediate utilized in the synthesis of Nordiazepam. This compound plays a crucial role in the development of anxiolytic and sedative agents by modulating GABAergic activity in the central nervous system. Its applications are primarily focused on drug discovery and development within the pharmaceutical industry, particularly in the formulation of therapeutic agents for anxiety and sleep disorders. -
Drug Impurity
Cinacalcet impurity 1 is a chemical impurity associated with Cinacalcet, a calcimimetic agent targeting the calcium-sensing receptor. This impurity is primarily used in pharmaceutical research to evaluate the purity and formulation of Cinacalcet, ensuring compliance with quality control protocols in drug development. It serves as an important reference standard for analytical purposes. -
Drug Impurity
N-(4-(N-(Cyclohexylcarbamoyl)sulfamoyl)phenethyl)-6-methylpyrazine-2-carboxamide, known as Glipizide Impurity, serves as a chemical impurity in the synthesis of the antidiabetic agent Glipizide. This compound can be utilized to investigate the stability, purity, and quality of pharmaceutical formulations containing Glipizide. Researchers studying drug metabolism and impurity profiles in pharmaceutical contexts may find this reagent valuable for their analytical and quality control applications. -
Drug Impurity
Rivaroxaban impurity 3 is a known impurity associated with the anticoagulant Rivaroxaban. This compound is utilized primarily in analytical chemistry for the quality control and characterization of Rivaroxaban formulations. Its identification and quantification are essential for ensuring the purity and safety of pharmaceutical products containing Rivaroxaban. -
Drug Impurity
Azilsartan impurity 10 is a chemical impurity related to the antihypertensive agent Azilsartan. This compound serves as a reference standard for analytical methods used in the characterization and quantification of drug impurities. Its use is essential in the development and quality control of pharmaceutical formulations to ensure compliance with regulatory standards. -
Drug Impurity
Escitalopram impurity 3 is a known impurity of the selective serotonin reuptake inhibitor Escitalopram, primarily involved in the pharmacological modulation of serotonin levels in the brain. Its characterization is essential for ensuring the quality and safety of pharmaceutical formulations containing Escitalopram. This reagent serves as a reference standard in studies focusing on impurity profiling and the evaluation of product stability in drug development and quality control processes. -
Drug Impurity
Sildenafil impurity 16 is a chemical impurity related to the phosphodiesterase type 5 (PDE5) inhibitor Sildenafil. As an impurity, it may be of interest in analytical chemistry for purity assessment and characterization of Sildenafil formulations. This compound is crucial for quality control and compliance in pharmaceutical development, particularly in the synthesis and evaluation of PDE5 inhibitors. -
Drug Impurity
Acyclovir impurity 5 is a characterized impurity of Acyclovir, an antiviral medication targeting viral DNA polymerase. This compound is essential for the evaluation of drug purity and safety, making it useful in the analysis of formulation quality and compliance with regulatory standards in pharmaceutical development. It serves as a crucial reference material for method validation and quality control in laboratories engaged in antiviral research and drug formulation studies. -
Betahistine Impurity
N,N-Dimethyl-2-pyridineethylamine is an identified impurity of Betahistine, a medication primarily used for the treatment of vestibular disorders. This compound serves as a useful reference standard in the analysis of Betahistine's purity and quality in pharmaceutical research. Its presence may influence the pharmacokinetics and safety profile of Betahistine, making it significant for analytical and quality control laboratories engaged in drug development and testing. -
Drug Impurity
Dexmedetomidine impurity 5 is identified as N-Ethylmedetomidine, a structural impurity of Dexmedetomidine. This compound plays a critical role in quality control and analytical studies to ensure the purity and safety of dexmedetomidine formulations. Researchers may utilize this impurity to investigate its effects in pharmacokinetic and toxicological assessments, thereby contributing to a better understanding of drug metabolism and efficacy. -
Drug Impurity
Trimetazidine impurity 5 is a drug impurity associated with trimetazidine, a medication primarily used for the treatment of angina pectoris. This compound serves as an important reference standard for the analysis and characterization of trimetazidine formulations in pharmaceutical research. It is essential for ensuring the quality and purity of drug substances, facilitating the development and validation of analytical methods in drug testing and quality control. -
Drug Impurity
Trazodone impurity 10, also known as Trazodone N-Oxide, is a known impurity found in Trazodone synthesis. Its presence can influence the pharmacological profile and safety evaluation of Trazodone formulations. This compound serves as a valuable reference for analytical method development, quality control, and stability studies within pharmaceutical research focused on Trazodone-related compounds. -
Drug Impurity
Beclometasone dipropionate impurity 3 is a known impurity associated with Beclometasone dipropionate, a corticosteroid medication. This compound can be utilized in the assessment of drug purity and stability, contributing to the quality control of pharmaceutical formulations. Researchers may employ this impurity in analytical testing protocols to ensure compliance with regulatory standards in drug development and manufacturing processes. -
Drug Impurity
Roxithromycin impurity 4, also known as Roxithromycin impurity D, is a chemical byproduct associated with the antibiotic Roxithromycin. This impurity can be utilized in research focused on the synthesis and characterization of drug formulations, particularly in assessing the quality and stability of Roxithromycin. Understanding impurities like Roxithromycin impurity 4 is crucial for regulatory compliance and ensuring the safety and efficacy of pharmaceutical products. -
Drug Impurity
Atorvastatin impurity 2 calcium is a known impurity of the cholesterol-lowering agent Atorvastatin calcium. This compound is utilized primarily in the quality control and analytical assessment of Atorvastatin formulations to ensure purity and compliance with pharmacopoeial standards. The characterization of this impurity is essential for researchers engaged in pharmaceutical development and regulatory submissions. -
Drug Intermediate
DOTA-PEG4-OSu is a bifunctional conjugate that combines a chelating agent with a PEG-based linker. It serves as a crucial intermediate for synthesizing radionuclide reagents, specifically 68Ga-DOTA-PEG4-(GGG-cKiE)2. This compound is instrumental in radiopharmaceutical applications, particularly in the development of targeted imaging agents for diagnostic purposes. -
Drug Impurity
Linagliptin impurity 1, also known as Bromo butene linagliptin impurity VII, is a specific drug impurity associated with Linagliptin. This compound may serve as a reference standard in analytical studies focused on the purity assessment and quality control of Linagliptin formulations. Researchers can utilize this impurity to evaluate the presence and concentration of impurities during the development and manufacturing processes of related pharmaceutical products. -
Drug Impurity
Atenolol impurity 6 is a byproduct of Atenolol synthesis. As a drug impurity, it serves as an important reference standard for quality control and analytical testing in pharmaceutical development. This compound is utilized to assess the purity of Atenolol and to study its potential effects during formulation and stability testing. -
Drug Impurity
Citalopram impurity 4 oxalate, also known as 3-Oxocitalopram oxalate, is a recognized impurity associated with the synthetic pathway of Citalopram oxalate. This compound serves as a crucial standard in pharmaceutical quality control, enabling the identification and quantification of impurities in Citalopram formulations. Its presence is relevant in research focused on drug metabolism and the assessment of drug purity and safety in pharmacological studies.
